The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

5,400

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 20, 2024

Study Completion Date

December 30, 2024

Conditions
Malaria,Falciparum
Interventions
BIOLOGICAL

Mosquirixs

RTS,S is a subunit vaccine that includes a portion of the circumsporozoite protein (CSP) co-expressed with Hepatitis B surface antigen. The adjuvant is AS01. Three doses of the vaccine will be administered, each with one month interval.

DRUG

artemether-lumefantrine

A therapeutic dose of artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) will be given twice a day for 3 days based on the weight of the child as per treatment guidelines.

All Listed Sponsors
collaborator

Ministry of Health, Malawi

OTHER_GOV

collaborator

Boston University

OTHER

collaborator

Michigan State University

OTHER

lead

Kamuzu University of Health Sciences

OTHER

NCT06424002 - The Impact RTS,S/AS01 Vaccine in School Aged Children RTS,S/AS01 Malaria Vaccine in School Aged Children | Biotech Hunter | Biotech Hunter